Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reversing Drug Resistance In Vivo

1 Jul 2004

Abstract excerpt

Apoptotic defects occur in oncogenesis and contribute to drug resistance. We have shown that Bcl-2, Akt, and the translational regulator eIF4E cooperate with Myc during lymphomagenesis and are potent inducers of drug resistance. Interestingly, lymphomas expressing Akt, but not those expressing Bcl-2 are sensitized to chemotherapy-induced apoptosis by the mTOR inhibitor rapamycin, an effect that is countered by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cell death mechanisms and regulation
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15190206
DOI: 10.4161/cc.3.7.976

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reversing Drug Resistance In VivoPMID 15190206Read ↗

Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1Semantic proximity Read ↗

Mechanisms of targeted therapy resistance take a de-TOR.Semantic proximity Read ↗

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axisSemantic proximity Read ↗

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models.Semantic proximity Read ↗

Determinants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations In vivoSemantic proximity Read ↗

PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.Semantic proximity Read ↗

Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapySemantic proximity Read ↗

mTORC1 promotes survival through translational control of Mcl-1Semantic proximity Read ↗

Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell LymphomasSemantic proximity Read ↗

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.Semantic proximity Read ↗

ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer.Semantic proximity Read ↗

Altering chemosensitivity by modulating translation elongation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.